Myles J F Smith1, Paul F Ridgway2, Charles N Catton3, Amanda J Cannell1, Brian O'Sullivan3, Lynn A Mikula4, Julia J Jones5, Carol J Swallow6. 1. The University of Toronto Sarcoma Group, Princess Margaret Hospital and Mount Sinai Hospital, Canada; Department of Surgery, University of Toronto, Canada. 2. Department of Surgery, Adelaide and Meath Hospital, Dublin 24, Ireland. 3. The University of Toronto Sarcoma Group, Princess Margaret Hospital and Mount Sinai Hospital, Canada; Department of Radiation Oncology, University of Toronto, Canada. 4. The Peterborough Clinic, Peterborough, Canada. 5. The R. S. McLaughlin Durham Regional Cancer Centre, Oshawa, Canada. 6. The University of Toronto Sarcoma Group, Princess Margaret Hospital and Mount Sinai Hospital, Canada; Department of Surgery, University of Toronto, Canada. Electronic address: cswallow@mtsinai.on.ca.
Abstract
BACKGROUND: Late failure is a challenging problem following resection of retroperitoneal sarcoma (RPS). We investigated the effects of preoperative XRT plus dose escalation with early postoperative brachytherapy (BT) on long-term survival and recurrence in RPS. METHODS: From June 1996 to October 2000, eligible patients with resectable RPS were entered onto a phase II trial of preoperative XRT (45-50 Gray) plus postoperative BT (20-25 Gray). Kaplan Meier survival curves were constructed and compared by log rank analysis (SPSS 21.0). RESULTS: All 40 patients had preoperative XRT and total gross resection as part of the prospective trial, nineteen received BT (48%). Median follow-up was 106 months. For the entire cohort, OS at 5 and 10 years was 70% and 64%, respectively; RFS at 5 and 10 years was 69% and 63%. RFS was significantly reduced in high versus low grade RPS at 5 years (53% vs. 88%, p=0.016), but not at 10 years (53% vs. 75%, p=0.079). RFS and OS at 10 years were reduced in patients who presented with recurrent compared to primary disease (RFS 30% vs. 74%, p=0.015; OS 36% vs. 76%, p=0.036). At 10 years, neither RFS nor OS was improved in patients who received BT compared to those who did not (RFS 56% vs. 69%, p=0.54; OS 52% vs.76%, p=0.23). CONCLUSIONS: In this prospective trial with mature follow-up, long-term OS and RFS in patients who underwent combined preoperative XRT plus resection of RPS compare favourably with those reported in retrospective institutional and population-based series. Postoperative BT was associated with unacceptable toxicity and did not contribute to disease control. CONDENSED ABSTRACT: In a prospective trial with mature follow-up, preoperative radiation combined with complete resection of retroperitoneal sarcoma resulted in favourable long-term RFS and OS compared to historical controls. Dose escalation with postoperative brachytherapy was not associated with better disease control.
BACKGROUND:Late failure is a challenging problem following resection of retroperitoneal sarcoma (RPS). We investigated the effects of preoperative XRT plus dose escalation with early postoperative brachytherapy (BT) on long-term survival and recurrence in RPS. METHODS: From June 1996 to October 2000, eligible patients with resectable RPS were entered onto a phase II trial of preoperative XRT (45-50 Gray) plus postoperative BT (20-25 Gray). Kaplan Meier survival curves were constructed and compared by log rank analysis (SPSS 21.0). RESULTS: All 40 patients had preoperative XRT and total gross resection as part of the prospective trial, nineteen received BT (48%). Median follow-up was 106 months. For the entire cohort, OS at 5 and 10 years was 70% and 64%, respectively; RFS at 5 and 10 years was 69% and 63%. RFS was significantly reduced in high versus low grade RPS at 5 years (53% vs. 88%, p=0.016), but not at 10 years (53% vs. 75%, p=0.079). RFS and OS at 10 years were reduced in patients who presented with recurrent compared to primary disease (RFS 30% vs. 74%, p=0.015; OS 36% vs. 76%, p=0.036). At 10 years, neither RFS nor OS was improved in patients who received BT compared to those who did not (RFS 56% vs. 69%, p=0.54; OS 52% vs.76%, p=0.23). CONCLUSIONS: In this prospective trial with mature follow-up, long-term OS and RFS in patients who underwent combined preoperative XRT plus resection of RPS compare favourably with those reported in retrospective institutional and population-based series. Postoperative BT was associated with unacceptable toxicity and did not contribute to disease control. CONDENSED ABSTRACT: In a prospective trial with mature follow-up, preoperative radiation combined with complete resection of retroperitoneal sarcoma resulted in favourable long-term RFS and OS compared to historical controls. Dose escalation with postoperative brachytherapy was not associated with better disease control.
Authors: Daniel P Nussbaum; Paul J Speicher; Brian C Gulack; Asvin M Ganapathi; Brian R Englum; David G Kirsch; Douglas S Tyler; Dan G Blazer Journal: Ann Surg Date: 2015-07 Impact factor: 12.969
Authors: Yuliya Olimpiadi; Suisui Song; James S Hu; George R Matcuk; Shefali Chopra; Burton L Eisenberg; Stephen F Sener; William W Tseng Journal: Curr Oncol Rep Date: 2015-08 Impact factor: 5.075
Authors: Philip Wong; Peter Houghton; David G Kirsch; Steven E Finkelstein; Arta M Monjazeb; Meng Xu-Welliver; Adam P Dicker; Mansoor Ahmed; Bhadrasain Vikram; Beverly A Teicher; C Norman Coleman; Mitchell Machtay; Walter J Curran; Dian Wang Journal: J Natl Cancer Inst Date: 2014-10-18 Impact factor: 13.506
Authors: William W Tseng; Carol J Swallow; Dirk C Strauss; Sylvie Bonvalot; Piotr Rutkowski; Samuel J Ford; Ricardo J Gonzalez; Rebecca A Gladdy; David E Gyorki; Mark Fairweather; Kyo Won Lee; Markus Albertsmeier; Winan J van Houdt; Magalie Fau; Carolyn Nessim; Giovanni Grignani; Kenneth Cardona; Vittorio Quagliuolo; Valerie Grignol; Jeffrey M Farma; Elisabetta Pennacchioli; Marco Fiore; Andrew Hayes; Dimitri Tzanis; Jacek Skoczylas; Max L Almond; John E Mullinax; Wendy Johnston; Hayden Snow; Rick L Haas; Dario Callegaro; Myles J Smith; Toufik Bouhadiba; Anant Desai; Rachel Voss; Roberta Sanfilippo; Robin L Jones; Elizabeth H Baldini; Andrew J Wagner; Charles N Catton; Silvia Stacchiotti; Khin Thway; Christina L Roland; Chandrajit P Raut; Alessandro Gronchi Journal: Ann Surg Oncol Date: 2022-06-29 Impact factor: 4.339
Authors: J Jakob; A Gerres; U Ronellenfitsch; L Pilz; M Wartenberg; B Kasper; H-R Raab; P Hohenberger Journal: Chirurg Date: 2018-01 Impact factor: 0.955
Authors: Daniel P Nussbaum; Paul J Speicher; Brian C Gulack; Asvin M Ganapathi; Jeffrey E Keenan; Sandra S Stinnett; David G Kirsch; Douglas S Tyler; Dan G Blazer Journal: Surg Oncol Date: 2014-07-23 Impact factor: 3.279
Authors: A Montero; M Nuñez; O Hernando; E Vicente; R Ciervide; D Zucca; E Sanchez; M López; Y Quijano; M Garcia-Aranda; R Alonso; J Valero; X Chen; B Alvarez; P Fernandez-Leton; C Rubio Journal: Rep Pract Oncol Radiother Date: 2020-06-09